Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Daniel P HurkmansSebastiaan D T SassenKarlijn de JoodeLisanne PutterEdwin A BasakAnnemarie J M WijkhuijsMarkus JoergerReno DebetsBirgit C P KochCor H Van der LeestMarco W J SchreursAstrid A M van der VeldtJoachim G J V AertsRon H J MathijssenStijn L W KoolenPublished in: Journal for immunotherapy of cancer (2021)
High interpatient variability of pembrolizumab PK is determined by BSA and serum albumin (on CL) and LDH (on Vd). A strong inverse CL-OS relationship was demonstrated for NSCLC and MPM, which could not be observed for melanoma and UCC. The findings suggest that personalized dosing should be prospectively explored.